X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: Avalere and FasterCures develop new value framework from patient perspective

By Holly Campbell  |    May 31, 2017
In case you missed it, a year-long collaboration between Avalere and FasterCures has resulted in the first value framework from the patient perspective. Unlike other frameworks which include limited...   Read More

Fighting multiple sclerosis: New Together ad illuminates the journey of patient & scientist

By Robert Zirkelbach  |    May 31, 2017
Meet Laurel and Ian. Laurel is a patient living with multiple sclerosis (MS), and Ian is a scientist developing new treatments to help Laurel and the other 2.3 million people with MS live longer,...   Read More

Medicare Monday: Catch up on MedPAC and its Part B recommendations

By Nicole Longo  |    May 29, 2017
A long weekend is the perfect time to catch up on your reading list. For policy wonks, you can get up to speed with our Memorial Day reading list on the Medicare Payment Advisory Commission (MedPAC),...   Read More

Medicines have significantly increased chances of cancer survival around the globe

By Amey Sutkowski  |    May 24, 2017
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to the...   Read More

Administration’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

By Jay Taylor  |    May 23, 2017
In the latest publication of its annual Special 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges in...   Read More

Medicare Monday: Did you know Medicare Part B uses a market-based system to pay for medicines?

By Nicole Longo  |    May 22, 2017
We often discuss the creation of Part D when we talk about the market-based changes that the Medicare Modernization Act (MMA) made to Medicare, but that’s just one example. Today, let’s take a closer...   Read More

Compulsory licensing: A misused and abused international trade law

By Jay Taylor  |    May 16, 2017
To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing...   Read More

Medicare Monday: Why imposing Medicaid-style rebates in Part D is a bad idea

By Nicole Longo  |    May 15, 2017
We’ve talked a lot about how repealing the non-interference clause in Medicare Part D would negatively impact beneficiaries. But there are other proposals to fundamentally alter the structure of Part...   Read More

A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements

By Robert Zirkelbach  |    May 15, 2017
Today, we released the latest chapter of GOBOLDLY™ advertising titled New World, featuring the extraordinary breakthroughs in science being discovered by biopharmaceutical researchers.   Read More

ICYMI: New study shows medicines advance life expectancy for HIV patients

By Andrew Powaleny  |    May 15, 2017
In the three decades since the HIV/AIDS crisis first struck the United States, incredible strides have been made in understanding and treating this disease.   Read More

Former law enforcement officials raise concerns with drug importation proposals

By Nicole Longo  |    May 11, 2017
Time and again, proponents of drug importation schemes overlook the major impact such proposals would have on our law enforcement officers – the men and women who spend their lives protecting...   Read More

Why won’t the insurance industry tell the truth about medicine costs?

By Robert Zirkelbach  |    May 10, 2017
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care...   Read More

Government-imposed price controls threaten innovation and access

By Jay Taylor  |    May 9, 2017
It’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any...   Read More

Medicare Monday: How finding an Alzheimer’s treatment could lower Medicare spending

By Nicole Longo  |    May 8, 2017
Alzheimer’s disease is devastating and impacts more than 5.5 million Americans and their families. While America’s biopharmaceutical researchers have been working tirelessly to find a cure for the...   Read More

ICYMI: Innovative payment models helping provide patient access to new medicines

By Holly Campbell  |    May 5, 2017
As we continue to make remarkable strides to treat our most costly and challenging diseases, there is a renewed focus on ensuring patients have access to the most innovative medicines. Increasingly,...   Read More

Guest Post: The Clinical trial experience from a patient & researcher perspective

By Guest Contributor  |    May 5, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

By Mark Grayson  |    May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...   Read More

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

By Holly Campbell  |    May 4, 2017
We have seen a deluge of data recently from government actuaries and pharmacy benefit managers showing a dramatic slowdown in medicine spending growth. And the QuintilesIMS Medicines Use and Spending...   Read More

Guest Post: Patients as research partners - Rethinking patient access to clinical trial data

By Guest Contributor  |    May 4, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Guest Post: Spotlighting the heroes in clinical trials

By Guest Contributor  |    May 3, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Guest Post: Advancing oncology research through clinical trials

By Guest Contributor  |    May 2, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Illegal trade barriers discriminate against U.S. innovators

By Jay Taylor  |    May 2, 2017
America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American workers....   Read More

Clinical Trials Awareness Week: Celebrating the impact of clinical research

By Andrew Powaleny  |    May 1, 2017
Today starts off the beginning of Clinical Trials Awareness Week, which shines a spotlight on how the clinical trials process helps deliver safe, effective medicines to patients.   Read More

Medicare Monday: What the experts are saying about the Independent Payment Advisory Board

By Nicole Longo  |    May 1, 2017
The Independent Payment Advisory Board (IPAB), a panel of 15 members selected by the President and confirmed by the Senate, is tasked with proposing cuts to Medicare if spending exceeds a certain...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates